Scholarlink

<p>Sarcopenia, defined by the progressive decline of skeletal muscle mass, strength, and performance, is an important, yet often overlooked complication of rheumatic and musculoskeletal diseases (RMDs). It arises from a multifactorial interplay of chronic systemic inflammation, oxidative stress, hormonal dysregulation, mitochondrial dysfunction, and prolonged glucocorticoid therapy. Elevated pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-1β, promote catabolic pathways, impair regeneration, and accelerate muscle degradation. The prevalence of sarcopenia in RMDs may reach 40%, particularly among patients with rheumatoid arthritis, osteoarthritis, and spondyloarthritis. Clinically, it contributes to frailty, disability, increased risk of falls and fractures, and higher mortality. Diagnostic assessment combines muscle strength and performance testing with imaging modalities, including DXA, CT, and ultrasound. Evidence supports multimodal interventions, integrating progressive resistance training, adequate protein intake (1.2–1.5&#xa0;g/kg/day), and supplementation with branched-chain amino acids, calcium, and vitamin D. Anti-inflammatory agents such as biologic DMARDs may counteract muscle loss while chronic corticosteroid use exacerbates it. Early recognition and multidisciplinary management are essential to preserve muscle function, improve quality of life, and reduce long-term morbidity in patients with RMD-associated sarcopenia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sarcopenia in rheumatic and musculoskeletal diseases: pathophysiology, diagnosis, and management

  • 期刊论文

  • 发表日期：

    2025年11月6日

查看全文
  • Yuliya Fedorchenko,
  • Nurzhamal Imanbayeva,
  • Umida Khojakulova,
  • Meirgul I. Assylbek,
  • Olena Zimba

摘要

Sarcopenia, defined by the progressive decline of skeletal muscle mass, strength, and performance, is an important, yet often overlooked complication of rheumatic and musculoskeletal diseases (RMDs). It arises from a multifactorial interplay of chronic systemic inflammation, oxidative stress, hormonal dysregulation, mitochondrial dysfunction, and prolonged glucocorticoid therapy. Elevated pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-1β, promote catabolic pathways, impair regeneration, and accelerate muscle degradation. The prevalence of sarcopenia in RMDs may reach 40%, particularly among patients with rheumatoid arthritis, osteoarthritis, and spondyloarthritis. Clinically, it contributes to frailty, disability, increased risk of falls and fractures, and higher mortality. Diagnostic assessment combines muscle strength and performance testing with imaging modalities, including DXA, CT, and ultrasound. Evidence supports multimodal interventions, integrating progressive resistance training, adequate protein intake (1.2–1.5 g/kg/day), and supplementation with branched-chain amino acids, calcium, and vitamin D. Anti-inflammatory agents such as biologic DMARDs may counteract muscle loss while chronic corticosteroid use exacerbates it. Early recognition and multidisciplinary management are essential to preserve muscle function, improve quality of life, and reduce long-term morbidity in patients with RMD-associated sarcopenia.